Clene Inc., a clinical-stage biopharmaceutical company specializing in neurodegenerative disease research, will participate in the upcoming Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025. The conference, hosted at The Venetian Resort in Las Vegas, Nevada, will bring together innovative companies and institutional investors for strategic discussions and networking opportunities.
The event, organized by JonesTrading and supported by B2i Digital, Inc., will feature one-on-one meetings, fireside chats, panels, and networking sessions. Clene's CEO and President, Rob Etherington, highlighted the conference as a critical platform to share the company's progress and connect directly with potential investors.
Notable keynote speakers include Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization. The conference will also include a golf event and cocktail reception, providing additional networking opportunities for participants.
For Clene, the conference represents a significant chance to showcase its research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. The company's investigational therapy, CNM-Au8®, focuses on improving mitochondrial health and neuronal function through innovative approaches targeting cellular metabolism.
By participating in this conference, Clene aims to engage with institutional investors, potentially securing funding and support for its groundbreaking research in neurological treatments. The event offers a strategic platform for the company to communicate its scientific advances and future vision to key stakeholders in the investment community.
